Quality of life in Italian patients with Multiple endocrine neoplasia type 1 (MEN 1): results of an extensive survey

Table 7 Scores of HADS, IES-R, LOT-R and SF36 in MEN1 patients, stratified by number of drugs taken for MEN1 treatment

Drugs	n	Age	HADS-A	HADS -D	LOT-R	IES-R	SF36
Drugs		Age	HADS-A	HADS -D	LOT-R	IES-R	PF	RP	BP	GH	VT	SF	RE	MH
0–2 (1.43 ± 0.50)	41
Mean		44.60	8.82	8.63	15.36 ^a	28.53	88.02 ^a	75.60 ^a	77.75 ^a	57.51^a	59.53	72.97 ^a	72.26	65.48
SD ±		14.08	2.64	1.66	3.41	20.97	18.79	36.86	23.69	20.38	19.48	22.94	40.11	17.76
3–4 (3.34 ± 0.48)	29
Mean		50.24	8.55	8.62	13.51 ^a	29.31	77.65 ^a	61.20	65.65	51.44	56.86	65.79	74.55	69.17
SD ±		10.22	2.30	1.63	3.03	16.85	20.55	41.50	28.45	23.70	22.03	24.72	36.41	16.29
5–6 (5.16 ± 0.37)	6
Mean		49.16	9.66	9.33	12.83	37.33	62 ^a	20.83 ^a	46.66 ^a	29.83^a	44.16	41.5 ^a	48.66	65.33
SD ±		15.51	3.82	1.36	3.25	15.60342	28.07	29.22	25.37	17.89	16.25	15.02	34.41	18.70

HADS Hospital Anxiety and Depression Scale, HADS-A scores for anxiety, HADS-D scores for depression, LOT-R Life Orientation Test-Revised, IES-R Impact of Event Scale-Revised, SF-36 Variables of Study 36-item Short-Form Health Survey, PF Physical functioning, RP Role limitations due to physical health problems, BP Bodily pain, GH General health perceptions, VT Vitality, SF Social functioning, RE Role limitations due to emotional problems, MH General mental health
^ap < 0.05

ISSN: 1750-1172